| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0966 |
| Trial ID | ChiCTR2200056010 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ScTIL |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | Phase I clinical study on the tolerance and safety of ScTIL (enhanced receptor and chimeric antigen receptor modified circulating tumor infiltrating lymphocytes, ECAR-T) in patients with CD19 positive recurrent or refractory non-Hodgkin lymphoma |
| Year | 2022 |
| Country | China |
| Company sponsor | Jiangsu Province Hospital |
| Cohort 1 | |||||||||
|
|||||||||